














PTTitle: Improving the detection of infectious diseases in at-risk migrants with an innovative integrated multi-infection screening digital decision 
support tool (IS-MiHealth) in Primary care: a pilot cluster-randomized controlled trial    
Running title: Personalized migrants´ screening increases the detection of infections 
Authors:  Ethel Sequeira-Aymar 1,2, MD; Angeline Cruz3, MD; Miquel Serra-Burriel4 , PhD; Ximena di Lollo 2, MD; Alessandra Queiroga 
Gonçalves5-6, PhD; Laura Camps-Vilà7, MD; Marta M Monclus-Gonzalez8, MD; Elisa M Revuelta-Muñoz9, MD; Nuria Busquet-Solé10, MD; 
Susana Sarriegui-Domínguez11, MD; Aina Casellas3, PhD; Maria Rosa Dalmau Llorca5,12, PhD; Carina Aguilar-Martín5,13, PhD; Constanza 









© International Society of Travel Medicine 2021. Published by Oxford University Press. All

































































1Consorci d’Atenció Primària de Salut Barcelona Esquerra (CAPSBE) Casanova.  
 Carrer  Rosselló 161, 08036 Barcelona, Spain 
2 August Pi i Sunyer Biomedical Research Institute (IDIBAPS).  
  Carrer Rosselló, 149, Barcelona, Spain 
3 Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona).    Carrer Rosello 132, 40, 08036 Barcelona, Spain. 
4 Epidemiology, Biostatistics, and Prevention Institute, University of Zurich.  
 Rämistrasse 71, 8006 Zürich, Switzerland. 
5Unitat de Suport a la Recerca Terres de l’Ebre, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina 
(IDIAPJGol).  
43500 Tortosa, Tarragona, Spain. 
6Unitat Docent de Medicina de Família i Comunitària Tortosa-Terres de L`Ebre, Institut Català de la Salut.  
























7 Centre d´Atencio Primaria Plaça Catalunya, Institut Català de la Salut (ICS).  
Carrer Soler i March, 6, 08242 Manresa, Spain  
8 Centre d´Atencio Primaria Sagrada Família, Consorci Sanitari Integral (CSI).  
Carrer Còrsega 643, 08025 Barcelona, Spain 
9 Centre d´Atencio Primaria Rambla Ferran, Institut Català de la Salut (ICS).  
Carrer Rambla Ferran 44, 25007, Lleida, Spain 
10  Centre d´Atencio Primaria Sagrada Família, Institut Català de la Salut.  
Carrer St. Cristòfol, 34, 08243 Manresa, Barcelona, Spain. 
11 Centre d´Atencio Primaria 1 Maig, Institut Català de la Salut (ICS).  
Carrer De la Mercè, 5. 25003, Lleida, Spain  
12 Equip d’Atenció Primària Tortosa Est, Institut Català de la Salut.  
Avenida Generalitat 95, 43500, Tortosa, Tarragona, Spain 
13 Unitat d’Avaluació, Direcció d’Atenció Primària Terres de l’Ebre, Institut Català de la Salut, Tortosa. 
43500 Tarragona, Spain. 
























08007 Barcelona, Spain 
15 Universitat Autònoma de Barcelona, Bellaterra. 
08193 Cerdanyola del Vallès (Barcelona), Spain. 
16 Migrant Health Research Group, Institute for Infection and Immunity, St. George's, University of London, London. 
SW17 0RE London, United Kingdom. 
17 Department of Medicine Solna, Karolinska Institutet. 
 Solnavägen 17177, Solna (Stockholm), Sweden. 
 
 
The results of this study have been submitted and accepted as an oral communication to the ECCMID conference 2021.  
 



























Assistant Research Professor  
Barcelona Institute for Global Health. 






























Background: There are major shortfalls in the identification and screening of at-risk migrant groups. This study aims to evaluate the 
effectiveness of a new digital tool (IS-MiHealth) integrated into the electronic patient record system of primary care centres in detecting 
prevalent migrant infections. IS-MiHealth provides targeted recommendations to health professionals for screening  multiple infections, 
including HIV, hepatitis B and C, active tuberculosis, Chagas disease, strongyloidiasis, and schistosomiasis, based on  patient characteristics 
(including variables of country of origin, age, sex). 
Methods: A pragmatic pilot cluster-randomised controlled trial was deployed from March to December 2018. Eight primary care centres in 
Catalonia, Spain, were randomly allocated 1:1 to use of the digital tool for screening, or to routine care. The primary outcome was the monthly 
diagnostic yield of all aggregated infections. Intervention and control sites were compared before and after implementation with respect to their 
monthly diagnostic yield using regression models. This study is registered on ISRCTN (ISRCTN14795012). 
Results: 15,780 migrants registered across the 8 centres had at least one visit during the intervention period (March to December 2018), of 
which 14,598 (92.51%) fulfilled the criteria to be screened for at least one infection. There were 210 (2.57%) individuals from the intervention 
group with new diagnoses compared with 113 (1.49%) from the control group (OR:2.08 95%CI 1.63-2.64, p<0.001). The intervention centres 
raised their overall monthly diagnosis rate to 5.80 (95%CI 1.23-10.38, p=0.013) extra diagnoses compared to the control centres. This monthly 
























(2.72,[95%CI 0.43-5.00]; p=0.02) and was observed as well for the parasitic infections´ group (Chagas disease, strongyloidiasis, and 
schistosomiasis) 2.58 (95%CI 1.60-3.57; p<0.001). 
Conclusions: The IS-MiHealth increased screening rate and diagnostic yield for key infections in migrants in a population-based primary care 



























Migration is a complex and growing global phenomenon of critical importance to European countries, particularly in recent years with 
unprecedented rises in migration flows to and within the EU/EEA.1,2 Migrants face an increased burden of certain infections3 including HIV, 
viral hepatitis and tuberculosis(TB)4 compared to host population. Similarly, certain parasitic diseases not endemic in Europe are highly 
prevalent in migrant populations,5,6 Strongyloidiasis despite being considered endemic in Spain in the past7 it is much more prevalent in tropical 
and subtropical areas, particularly in those areas with poor hygienic conditions,8 with migrant population prevalence is estimated above 12%.9 
Chagas diseases is only endemic in migrant populations10 although at risk of community transmission in non-endemic areas.11 
In addition, despite limiting data on the impact of COVID-19 on morbidity and mortality among migrant population, particularly those living in 
refugee camps, detention or reception centres may be at particularly high risk for COVID-19 exposure.12 
Screening on arrival is almost non-existent and many countries historically have only focused on TB screening.13  One study in Sweden reported 
that a TB screening programme targeting refugees only contributed to 15% of the total cases, suggesting that with this approach other migrant 
groups are missed, and they could be potentially targeted in other settings such as Primary Care.14 In addition, moving from routine HIV testing 
from sexual health and antenatal clinics to non-traditional settings (e.g., Primary Care) to reduce the pool of undiagnosed HIV infection in the 
population is cost-effective.15   
Innovative integrated programmes, to deliver more cost-effective screening to high-risk migrants on arrival are a key step to meet global and 
























individual differences (gender, age, origin) of migrant related conditions often means that these infections go undetected. This contributes to 
worse health outcomes, widening  health inequities, and could sustain disease transmission with a high cost for health systems.16,17 Adopting 
multi-disease screening approach, is now considered a good strategy although its cost-effectiveness needs to be demonstrated in larger studies.18 
The ECDC published new guidance in 201819 calling for innovative strategies to deliver multi-disease screening to migrants. Data on cost-
effectiveness are scarce and limited to single disease screening, but they suggest moderate to high cost-effectiveness of migrant screening 
programs depending on migrant group and disease targeted.20–24 
With the aim of improving patient care by strengthening medical decisions, there has been a development of clinical decision support 
systems(CDSS) in the last decade.25 In such tools, the characteristics of an individual extracted from structured or unstructured data or both, are 
matched to a computerized algorithm with patient-specific assessments.25 The recommendations to the clinical staff to make a  decision can 
manifest as computerized reminders, or clinical workflow tools. The decrease in test duplication at primary care supports the cost-effectiveness 
of implementing CDSS in screening.26,27 Evidence on infections remains low, with some studies suggesting in an increased screening of hepatitis 
C by 5 fold.28 So far, no evidence on CDSS supporting the screening on migrant populations have been developed.   
We developed an innovative digital tool (IS-MiHealth) integrated into the electronic patient record(EPR) system of primary care that provides 
targeted recommendations through computer prompts to health professionals on screening migrant population for multiple infections . IS-
























of the IS-MiHealth tool including the increasing detection rate, the screening rate performed as well as the feasibility and acceptability of the 
tool.     
METHODS: 
Study design and setting 
A pragmatic pilot randomised cluster-controlled trial was implemented to assess the effectiveness of the digital tool IS-MiHealth conducted in 
eight primary care centres (PCC) randomized 1:1 located in four areas of Catalonia, Spain: Barcelona, Manresa, Lleida, and Tortosa from March 
to December 2018. All areas have a high migrant density accounting for 20% or more of the total population.29  
Population 
Eligible participants were migrants aged >16 years old, (excluding foreign-born population from Western Europe, North America, Australia, or 
New Zealand) who attended a visit at a PCC during the intervention period (March to December 2018) for any reason and who accepted to be 
screened according to the criteria of health professionals. No exclusion criteria was set concerning the year of arrival to provide the screening 
recommendation except for TB where a limit for five years since  arrival to the host country was established. This criterium was established due 
to all infections (except for TB) being chronic and also to the fact that for some of them, particularly HIV, the infection risk remains after the 
migration.30  
Health professionals offered eligible patients to be tested according to an individual risk assessment that included the country of origin, sex, and 
























oral consent was provided by the patients who agreed to be screened. As per the consent of minors aged 17, adults responsible of the minor 
should consent as well in the visit any screening test conducted. The blood tests and referrals to any specialist were performed according to the 
standard procedures of each centre.    
Screening recommendations based on individual risk assessment 
To develop the screening recommendations, including the selection of the infections to be screened and the screening criteria for each infection, 
European screening guidelines for migrants were comprehensively reviewed. Thereafter, a consensus workshop was conducted with Infectious 
diseases experts, primary care physicians, and  Public Health officers to develop a final screening algorithm with screening criteria for each 
condition that considered country of origin prevalence and incidence data. The screening algorithm included seven infections– HIV, hepatitis B 
and C, active TB, Chagas disease, strongyloidiasis and schistosomiasis - and has been published elsewhere.31 
Briefly, HIV serological test was offered following ECDC recommendations to individuals >16 years coming from countries with a prevalence 
>1%;32 active TB was screened through a chest radiography in migrants from countries with an incidence >50/100,000, as agreed in a consensus 
workshop and inspired by the pre-arrival TB screening programme reflected in the  NICE guidelines (United Kingdom) and introducing a time-
frame of 5 years since the arrival to the host country;33 HBV (HBs Antigen and HBV IgG) and HCV IgG serological tests were offered (also 
following ECDC guidelines) to those individuals >16 years coming from countries with >2% prevalence.19 Strongyloidiasis and Schistosoma 
serological tests were offered to those individuals >16 years coming from endemic areas, also defined in the ECDC guidelines.34 A Chagas 
























Countries of origin were aggregated into areas of origin adapting the international classification of the United Nations Statistics Division35 
(supplementary file 1). 
Health centres selection and randomisation   
First, a comparative analysis of the health centres in the study areas was performed to select the pairs of PCC in each area with more similar 
characteristics, including for each centre: number of health professionals, migration density, and mean socio-economic index of the population 
attended36 (supplementary file 2). Therefore, for each study area, two of the PCCs with more similar characteristic were selected, and the PCC 
were contacted (through their director) and invited to participate in the study. They were randomly assigned 1:1 in blocks using a matched pairs 
design with a statistical software to be an intervention or a control centre within each study area.   
The intervention procedure  
In the intervention centres the multi-disease screening programme was implemented using the IS-MiHealth tool. IS-MiHealth, set a series of logical 
rules that provide real-time prompts to health professionals on infectious diseases screening  for migrants37. For conducting the individual risk 
assessment, the tool displays reminders based on three variables -sex, age, and country of origin- that are directly collected by the administrative 
staff of the health centres, and that are routinely registered in the electronic patient record(EPR) system of PCC included in the study (Estació-
Clínica d’Atenció Primària-eCAP); therefore, when a migrant comes to the health centre for any reason, the health professional receives a pending 
task assignment with recommendation on the diseases that should be considered for screening based on this person’s background characteristics 
























(based on ICD-10 code diagnosis) or if a diagnostic test had been performed for any condition included in the program. This includes ICD-10 
codes registered and tests performed in other centres in Catalonia that use the same EPR (eCAP). In such cases, the automated electronic prompt 
does not appear for that condition (see explicative video at: https://vimeo.com/368313593).  
Health professionals from the intervention centres received automated electronic prompts with recommendations for screening if the individual 
meets screening criteria for each condition, alongside holding a standard training session. In the control centres, health professionals followed 
the routine care although they received a training session before the intervention started, where the screening algorithm was presented, and it was 
available to them for consultation. They were informed about the study and that they would be compared with other centres where the screening 
decision making tool would be implemented.  In both cases, health professionals were responsible for ordering a blood test or a chest 
radiography and to refer to the specialist if required.  
Training session  
Training sessions were  targeted to centres´ staff  including nurses, medical doctors, and other technicians. The session covered background 
information on each infection, including epidemiology, diagnostic tools, available treatments,  specific clinical aspects, or risk factors that may 
be of importance for some infections (e.g., immunosuppressant condition for Chagas disease or strongyloidiasis), screening recommendations 
and also the importance of the whole care pathway ensuring the access to any specialised care. A manual with the screening recommendation for 

























Serological tests and chest radiography in the case of TB were performed following the same procedures in all centres to screen each disease. 
The serological test for HIV and viral hepatitis were performed according to each centre referral laboratory . The Strongyloides serology was an 
ELISA test, (Kit based on IVD Strongyloides stercoralis crude antigen, SCIMEDX, Dover, NJ, USA) and Schistosoma tests was an indirect 
hemagglutination test -Schistosomiasis Fumouze). Laboratory diagnosis of T. cruzi infection was established by two serological ELISA tests, 
following international recommendations. One was a commercial ELISA with recombinant antigens (BioELISA Chagas, Biokit S.A., Barcelona, 
Spain), and the other was an in-house ELISA with whole T. cruzi epimastigotes antigen. Diagnosis of T. cruzi infection was defined by positivity 
in the two serological tests. All serological tests were available at PCC except the serology of strongyloidiasis and schistosomiasis that were not 
available in both intervention and control Tortosa centres . In case of a confirmed diagnosis, the individual was referred to the required specialist 
as appropriate for receiving specific treatment. 
Data  
Routine health data were extracted from the SIDIAP(Sistema d’Informació per al Desenvolupament de la Investigació en Atenció-Primària) 
database containing anonymized data. All data points in the control and intervention groups were obtained, with baseline data from the six years 
before the screening program implementation (January-2012) until the end of the intervention period (December-2018) of the migrant 
individuals attended in any of the eight centres including only structured variables routinely collected in the EPR. Data on diagnostics were 
extracted, including chest x-rays and serologies performed and test results  performed for HIV, HBV, and HCV, Chagas disease, 
























professionals. The additional information extracted was socio-demographic characteristics including age, sex, country of origin, entry and exit 
date to the PCCs, whether the patient fulfilled or not the screened criteria, number, and dates of visits to each centre from 2012 to 2018. 
Additionally, other data were extracted such as any immunosuppressant treatment or any ICD-10 code on cancer or autoimmune disease in 2018. 
Data analysis 
Summary statistics were presented as frequencies for categorical variables and as means (with standard deviations) for normally distributed 
continuous variables or medians (with IQR-Interquartile range) for non-normally distributed continuous variables. Associations were tested with 
Fisher-Exact tests for categorical variables and odds ratios were computed. Mixed-effects logistic regression models were used to identify 
associations between the screening rate performed and socio-demographic, and other health conditions, using area as a random intercept. The 
significance level was established at the 5% level. Sample size and statistical power was contingent on the budget to design and implement the 
pilot intervention. Assuming 2,000 subjects per cluster, with 4 sites in intervention and 4 control sites, 75 monthly periods before and 9 post 
intervention, and effect size of 1.5 standard deviations could be detected under a 5% significance level with 59% statistical power. 
The primary outcome measure was the monthly diagnostic yield of all aggregated imported conditions included in the study and all aggregated 
low-endemic conditions. Secondary outcomes were the aggregated monthly diagnostic yield of TB, HIV, HCV, HVB, Chagas disease, 
strongyloidiasis and schistosomiasis, the screening proportion for each condition and to evaluate factors associated with having a higher 
screening rate, such as sex, age, immunosuppression status, being attended in an intervention centre, fulfilling the screening criteria, or coming 
























generalized linear model. Intervention units were compared before and after implementation with respect to the average diagnostic rate of 2012-
2018. Sandwich-robust standard errors were clustered at the intervention-level. 
All data analyses were performed R-3.6.3 for the primary outcome. Packages described in the supplementary file 4. Stata 16 (Stata-Corp-
LP,USA) was used for secondary outcomes. The study was reported by using the CONSORT –extension checklist for cluster 
trials(supplementary file 5). 
Ethics and Registration 
This study was approved on 16/12/2016 by the Ethics committee of Hospital-Clínic, Barcelona(HCB/2016/0858) and IDIAPJGoL (IDIAP: 
4R17/066) . The study protocol was registered in the ISRCTN platform, ISRCTN14795012. 
 
RESULTS 
The eight PCCs in Catalonia had a reference population ranging from 16,122 to 30,831 people, of which 13,574 to 20,882 attended at least one 
visit during the intervention period. The total number of migrants with any record registered in the eight PCCs was 28,179, varying between 
centres from 2,070 to 6,188. A total of 15,780 (56.0%) individuals attended any of the eight centres in 2018 at least once (Figure 1). Lastly, the 
number of health professionals working in each PCCs ranged from 17 to 40. The main characteristics of the PCCs by study area are summarised 
























A total 14,598 (92.5%) of the total migrant population of the eight PCCs fulfilled the criteria to be screened for at least one condition according 
to the country of origin, sex, and age. Table 1 shows the percentage of individuals that fulfilled the screening criteria for each condition 
according to epidemiological background by study area and in both intervention and control PCCs. There were no differences in the percentage 
of people with criteria to be screened for any infection in the intervention PCCs compared with the control sites in three of the study areas 
(Table1); and in one area (Barcelona), a higher percentage of people with screening criteria for any infection was found in the intervention centre 
(table 1). Concerning parasitic infections, no differences were observed in two areas, a higher percentage of people fulfilling the screening 
criteria were observed in the control centre, and the other study area a higher percentage of people with screening criteria was observed in the 
intervention area.   
Diagnostic yield 
During the intervention period, there were a total of 210(2.6%) diagnoses (3 HIV, 148 hepatitis B, 7 hepatitis C, 4 active TB, 55 strongyloidiasis, 
2 schistosomiasis and 3 Chagas disease cases), in the intervention centres compared with 113 (1.5%) diagnoses in the control centres (9 HIV, 96 
hepatitis B, 5 hepatitis C, 6 active TB, 2 strongyloidiasis, 1 schistosomiasis and 1 Chagas diseases cases), Resulting in a relative increased yield 
measured as odds ratio of 2.1 95%CI (1.6-2.6,p<0.001). The monthly diagnostic yields are presented in Figure 2. The figure presents the locally 
smoothed trends of the intervention and control centres in diagnoses during the post intervention period and up to 6 years prior to 
implementation. Before implementation, there were no significant differences in monthly diagnostic rate between intervention and control PCCs 
























the intervention centres raised their overall monthly diagnostic rate to 5.8 (95%CI 1.2-10.4; p=0.013) extra diagnoses compared to the control 
group. This monthly increase in diagnosis in intervention sites was also observed if we consider all cases together of HIV, hepatitis B and C, and 
active TB cases (2.7, [95%CI 0.4-5.0]; p=0.02) and was observed as well for the parasitic infections´ group (Chagas diseases, strongyloidiasis, 
and schistosomiasis) 2.6 (95%CI 1.6-3.6; p<0.001). Supplementary file 8 displays the estimates alongside their uncertainty intervals. 
Secondary outcome: screening performance. 
The total screening tests performed across centres for each disease and the screening performance among those fulfilling the screening criteria 
are summarised in Table 2. The proportion of screening number for all diseases was significantly higher in the intervention vs control centres for 
all conditions. Among those who fulfilled the screening criteria, 201/1,373(14.6%) were screened for HIV in the intervention centres compared 
with 84/948(8.9%) in the control centres (HIV OR 1.6 [95%CI 1.2-2.1];p=0.002); for hepatitis B, 406/3,445(11.8%) were screened in the 
intervention centres vs 256/2,784 (9.2%)(HBV OR 1.3 [95%CI 1.1-1.5]; p=0.005); for HCV, 413/3,299 (12.5%) in the intervention centres vs 
236/2,644 (8.9%) in the control centres (HCV OR 1.4 [95%CI 1.2-1.7];p<0.001); for TB, 59/1168(5.1%) individuals were screened in the 
intervention centres vs 41/1,215(3.4%) (TB OR 1.6 [95%CI 1.1-2.4], p=0.027). The screening performance among those who fulfilled screening 
criteria for Chagas disease was 95/1,454 (6.5%) in the intervention centre compared with 20/1,663 (1.2%) individuals in the control centres (OR 
5.3 [95%CI 3.2-8.7]; p<0.001); for strongyloidiasis 373/5,878 (6.4%) individuals were screened in the intervention centres compared with 
























intervention centres compared with 1/685(0.2%) in the control centres  (OR 59.6, [95%CI 8.3-431.4]; p<0.001). Further details of the screening 
performance by study area is provided in Supplementary file 7. 
In the mixed effect adjusted logistic regression model for evaluating factors associated with the screening performed for any infectious diseases, 
patients that attended an intervention centre were 1.4 (95%CI 1.2-1.5; p<0.001) times more likely to have a screening test performed than those 
who attended the control centres. Females (OR 1.2, [95%CI 1.1-1.3], p<0.001), individuals with a known immunosuppressed status (1.5, 
[95%CI 1.3-1.7],p<0.001), and individuals with an Asian origin (OR 1.2, [ 95%CI 1.0-1.5]; p=0.035) were more likely to be tested (table 3A).   
When the screening performance of the parasitic infections (Chagas diseases, strongyloidiasis and schistosomiasis) was exclusively evaluated, an 
association was found with the intervention (OR 7.5, [95%CI 5.6-10.2]; p<0.001), with having fulfilled the screening criteria (OR 5.9, [95%CI 
2.7-12.9]; p<0.001), with an immunosuppressed status (1.5, 1.2-1.9, p<0.001) and with an American (OR 1.6, [95%CI 1.2-2.2]; p=0.001) and an 
Asian (OR 1.8 [95%CI 1.2-2.7]; p=0.004) origin.(table 3B)     
DISCUSSION 
Our study suggests an increased screening, detection, and diagnostic yield for all infections in intervention centres where the IS-MiHealth tool 
was implemented. In particular, the detection rate was increased for the parasitic infections (Chagas diseases, strongyloidiasis, and 
schistosomiasis). The total detection yield was much higher in the intervention group particularly for strongyloidiasis and for hepatitis B and this 
may be attributed to a better screening performance together with a higher number of individuals with screening criteria in both intervention and 
























yield was higher in control group for HIV and TB. The low numbers from this pilot study prevented to have conclusive results about the 
detection yield differences for each infection. We also found a higher screening proportion for all the conditions, and for the parasitic infections 
the likelihood of being tested was more than seven times higher in the intervention centres using the tool compared with the control centres. 
Therefore, our data shows that the implementation of our digital tool appears to modify the clinician behaviour with regards to routinely 
screening for infections in migrant populations and that guidelines or education alone are insufficient to influence practice. Besides fulfilling the 
screening criteria, other factors such as a patient immunosuppression have been also independently associated with a higher testing rate, 
suggesting that health professionals modify their diagnostic workup among this high-risk population. 
In recent years, there has been a call for clear guidance on screening and vaccination of migrant populations.19 It has been acknowledged that 
innovative and tested interventions should be designed and implemented with multi-disease screening approaches, and that primary care may be 
the best approach to ensure high uptake to screening.38 There have been multiple studies aimed to screen infections in the migrant 
populations.39,40 However, these screening programs are not based on an individual risk assessment of the cut-off prevalence of the infection in 
the country of origin as our program has established,31 only few of them are at primary care settings and they usually only include HIV, viral 
hepatitis, and TB.39 Furthermore, formal screening of new-arriving migrants in special clinics may miss many migrant groups compared to 
primary care where screening can be routinely delivered.41  
This study represents the first attempt to test an innovative CDSS that delivers and integrates a multi-infections screening program for migrants 
























clinician with targeted and tailored screening option, individualised to the patients´ risk factors. All of this, alongside to the fact of including 
infections that have evidence-based report a clear benefit to be screened for,19,20 and the fact of being a multi-disease approach, may reduce the 
cost impact on health system.42 Although there exist other screening tools for migrant, they usually target other topics such as mental health and 
they are not integrated in the EPR.43 
The IS-MiHealth tool is low cost to run (estimated around 10,000€ including its maintenance for 5 years in one EPR system) but further cost-
effectiveness and cost-analysis are now warranted and will be a focus of the next stage of this research. Studies demonstrating the cost-
effectiveness of targeting migrant population in screening programmes at primary care, have been performed for single diseases, including TB,24 
HIV,15 viral hepatitis,44 strongyloidiasis45 and Chagas disease.20 However, there is a lack of data on cost-effectiveness of multiple infections.  
Preliminary results of the qualitative assessment of IS-MiHealth show that the prompts helped the general practitioners to perform screening, 
especially in imported diseases that are unfamiliar to health professionals, highlighting the importance of continuous training in primary care. 
Further comprehensive and robust methodological feasibility studies should properly explore behavioural patterns in primary care doctors to 
improve the intervention's effectiveness. In addition, IS-MiHealth should be tested and assessed its feasibility in other European regions , what 
implies its integration in other EPR systems to assess the external validity of the results. Furthermore, other conditions that highly affects 
migrants, such as latent TB, vaccination uptake, female genital mutilation, or mental health among others, could also be included into the 
screening recommendations. Finally, the findings from this study could be used to advocate for the integration of the screening program into the 
























follow-up, since these objectives were beyond our study, we guaranteed the access to the whole care pathway to all individuals that were tested 
in our study; and this is an essential component that should be considered when implementing this kind of programmes.    
Strengths and limitations 
The main strength of this study design lies with the randomization of the algorithm implementation, its integration in the EPR system based on 
key structured variables routinely collected; also, the data extraction from the EPR system avoided the use of questionnaires for data collection 
purposes. Moreover, our study design allows to visually inspect the trends in outcomes of the intervention and control centres up to 6 years 
before implementation, providing further suggestive evidence that the estimated increase was caused by the program introduction. 
This study is not without limitations. First, the date of arrival to the country was not collected in the e-CAP system, thus not providing adequate 
information to fulfil the active TB screening criteria based on the IS-MiHealth recommendations (to screen migrants that arrived in the country 
within the last five years). Second, a technical limitation was regarding the missing values of key variables such as the country of origin for some 
migrant individuals although this percentage was estimated to be below 5%. In this regard, the registry of these variables among the 
administrative staff who collect the demographic data in the EPR system should be advocated and guaranteed.  The retrospective data collection 
may have led to inaccuracies or measurement error even if these were independent of the random assignment. For example, we could not verify 
the reason for being tested in both intervention and control centres and some patients may have been tested for reasons beyond the screening 
























was developed considering the country prevalence for each infection, but it could be further improved in subsequent iterations by including 
migrant data-driven approaches   
CONCLUSIONS 
This study provides suggestive evidence for the increased detection of infectious diseases in migrant populations, and in particular, for imported 
disease, following the implementation of a novel digital tool in primary care. Our results support integrated multi-disease screening programmes 
based on an individual risk assessment. Further studies should aim at validating the tool at a larger scale and assess its feasibility and efficiency 
as a previous step in the implementation of routine care. 
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Figure 1. Flow chart of the study population.  

























Figure 2.  Monthly diagnostic rates of the intervention and control PCC, before and after implementation, March 2018. 
Legend Figure 2: Monthly diagnostic rate local regression lines (LOESS) of outcomes intervention (red) and control (blue) centres. 



























PT Barcelona Manresa Lleida Tortosa Total 
 Control Intervention  Control Intervention  Control Intervention  Control Intervention  Control Intervention  
 n (%) n (%) p-
value 
n (%) n (%) p-
value 
n (%) n (%) p-
value 
n (%) n (%) p-
value 




2,343  1,161  1,423 1,864  1,929 3,410  1,914 1,736  7,609 8,171  
Immunosuppression 
status in 2018 
256 
(10.9) 
117 (10.1) 0.443 251 
(17.6) 
300 (16.1) 0.240 295 
(15.3) 
578 (17.0) 0.116 393 
(20.5) 





Region of origin 
Southern Europe 








Sub Saharan Africa 







































































































































































Sex (female) 1,454 
(62.1) 



















38.3 (12.4) 0.733 38.87 
(13.3) 
38.39 (12.9) 0.299 39.04 
(12.2) 









Screening criteria    




475 (40.9) <0.001 239 
(16.8) 
401 (21.5) 0.001 326 
(16.9) 
413 (12.1) <0.001 285 
(14.9) 





























124 (5.3) 31 (2.7) <0.001 146 
(10.3) 
170 (9.1) 0.272 415 
(21.5) 




































Screening criteria - 
HIV 
110 (4.7) 56 (4.8) 0.886 192 
(13.5) 
220 (11.8) 0.147 422 
(21.9) 
956 (28.0) <0.001 224 
(11.7) 
































351 (30.2) 0.033 405 
(28.5) 















262 (22.6) 0.961 384 
(27.0) 















443 (38.2)  <0.001 166 
(11.7) 
 182 (9.8) 0.079 206 
(10.7) 


























7,747 (94.8) <0.001 
























Table 2. Screening tests performed for infectious diseases included in the screening program 
among those who attended the PCC during the intervention. 




 Control Intervention OR (95% CI) p-value2 
Total population  7,609 8,171   
Number of T. cruzi disease screening tests  









Number of Strongyloides screening tests 









Number of Schistosoma screening tests 









Total screening number of any parasitic infection 









Number of HIV screening tests 









Number of HBV screening tests 









Number of HCV screening tests 









Number of active TB screening tests 









Number of screening tests for any condition    



































Table 3. Factors associated with being screened for any infectious diseases (3A) and for 








 Crude OR (95% CI) p-value Adjusted OR (95% CI)1 p-value 
Screening criteria 1.16 (0.96-1.38) 0.120     1.07 (0.88-1.31) 0.494
 
Group Intervention 1.34 (1.22-1.46) <0.001     1.35 (1.23-1.48) <0.001 
Age  1.00 (0.99-1.00) 0.042     1.00 (0.99 -1.00) 0.007 
Sex (female) 1.21 (1.10-1.32) <0.001     1.22 (1.11-1.33) <0.001 
Continent2 (origin) 
    Europe 
    America 
    Africa 
    Asia 
    Oceania 
 
Base 
  1.03 (0.91-1.17) 
  1.06 (0.95-1.18) 
  1.22 (1.03-1.46)                 






0.196                                                                                                          
 
   Base 
   0.98 (0.86-1.13) 
   1.04 (0.93-1.18) 
   1.22 (1.01-1.46) 














   1.47 (1.32-1.65) 
 
<0.001 
1.Mixed effect logistic regression model 2. European countries exclude Spain;  
3B 
 Crude OR (95% CI) p-value Adjusted OR (95% CI)1 p-value 
Screening criteria 17.13 (4.24-69.12) <0.001 5.92 (2.72-12.88) <0.001
 
Group Intervention 7.78 (5.77-10.49) <0.001 7.51 (5.56-10.15) <0.001 
Age 1.01(1.00-1.02) 0.005 1.01 (1.00-1.02) 0.012 
Sex (female) 1.14 (0.94--1.38) 0.183 1.18 (0.97-1.44) 0.098 
Continent2 (origin) 
  Europe 
  America 
  Africa 
  Asia 



























1.59 (1.26-2.00) <0.001 1.53 (1.22-1.94) <0.001 
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